Additionally, FCRL2-6, A, and B are associated with activation and inhibition of the hormone estrogen receptor (ER), which plays a crucial role in the development and progression of hormone-sensitive tumors, such as breast and endometrial cancer [28–30]. Here, ESR1 is linked to endometrial cancer.